Abstract: An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A(1-4)-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional analogues capable of binding to an antigenic epitope within the A(1-4)-D region of human tenascin.

Abstract: An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A(1-4)-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional analogues capable of binding to an antigenic epitope within the A(1-4)-D region of human tenascin.

Abstract: A peptide of formula (I) (H2N—X1—Thr—X2—CO)n—R  (I) where X1 and X2, different one another, are an amino acid residue of arginine or tyrosine in configuration L or D, wherein the hydroxy group of threonine and tyrosine and the guanidine moiety of arginine may be protected by a compound conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 1,2, 3 or 4, and R, when n is 2,3 or 4, is a group suitable for forming a dimer, trimer or tetramer, while, when n is 1, R is OH, a single amino acid residue, or a peptide chain contains up to 7 amino acid residues.

Abstract: The present invention relates to a pharmaceutical composition comprising a biologically effective amount of a peptide of formula (I) (H2N—X1—CO—Thr—NH—X2—CO)n—R  (I) where NH—X1—CO and NH—X2—CO which are different from one another, are residues of tyrosine or arginine, in L or D configuration, where the hydroxy group of threonine and the guanidine moiety of arginine may be protected by a group conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 2, 3, or 4, R is a group capable of forming a dimeric, trimeric, or tetrameric peptide, and a pharmaceutically acceptable inert carrier.

Abstract: Use of a peptide compound of formula (H2N-X1-Thr-X2-CO)n-R  (I) wherein X1, X2, n and R have the meanings stated in the description for preparing a pharmaceutical composition useful in the treatment of Systemic Lupus Erythematosus.

Abstract: An improved antigenic peptide where the amino acid sequence is modified by replacing one or more amino acids with glycine.

Abstract: A peptide of formula (I) (H2N—X1—Thr—X2—CO)n—R  (I) where X1 and X2, different one another, are an amino acid residue of arginine or tyrosine in configuration L or D, wherein the hydroxy group of threonine and tyrosine and the guanidine moiety of arginine may be protected by a compound conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 1,2, 3 or 4, and R, when n is 2,3 or 4, is a group suitable for forming a dimer, trimer or tetramer, while, when n is 1, R is OH, a single amino acid residue, or a peptide chain containing up to 7 amino acid residues.

Abstract: An improved antigenic peptide where the amino acid sequence is modified by replacing one or more amino acids with glycine.

Abstract: A peptide of formula (I)(H.sub.2 N--X.sub.1 --Thr--X.sub.2 --CO).sub.n --R (I)whereX.sub.1 and X.sub.2, different one another, are an amino acid residue of arginine or tyrosine in configuration L or D, wherein the hydroxy group of threonine and tyrosine and the guanidine moiety of arginine may be protected by a compound conventionally used in peptide chemistry for protecting the hydroxy group and the guanidine moiety, respectively, n is 1, 2, 3 or 4, andR, when n is 2, 3 or 4, is a group suitable for forming a dimer, trimer or tetramer, while, when n is 1, R is OH, a single amino acid residue, or a peptide chain containing up to 7 amino acid residues.

Abstract: A mobile-module plant (1) for the development and the production of biotechnological products on a pilot scale comprising equipments for the production, separation, purification and finishing of said products (11, 17, 18, 19, 20; 40, 47, 48, 50, 52, 54; 71-76, 82, 86, 89, 92, 95, 98) and auxiliary equipments (102; 107, 109, 110; 112; 113; 119; 123; 129; 134; 135; 141-143), wherein (i) the plant (1) consists of at least two mobile modules (2; 3; 4; 5; 8) suitable for being connected together and integrated one with the other. Each of the mobile modules (2; 3; 4; 5; 8) comprises a movable container (6). At least one of the movable containers (6) is provided with a preselected own set of said equipments (11, 17, 18, 19, 20; 40, 47, 48, 50, 52, 54; 71-76, 82, 86, 89, 92, 95, 98; 102; 107, 109, 110; 112; 113; 119; 123; 129; 134; 135; 141-143). At least one of the movable containers (6) is aseptic.